WO1993001820A3 - Inhibition de l'infection hiv a mediation par la proteine non-cd4 - Google Patents

Inhibition de l'infection hiv a mediation par la proteine non-cd4 Download PDF

Info

Publication number
WO1993001820A3
WO1993001820A3 PCT/US1992/005985 US9205985W WO9301820A3 WO 1993001820 A3 WO1993001820 A3 WO 1993001820A3 US 9205985 W US9205985 W US 9205985W WO 9301820 A3 WO9301820 A3 WO 9301820A3
Authority
WO
WIPO (PCT)
Prior art keywords
hiv infection
inhibition
mediated hiv
hiv
methods
Prior art date
Application number
PCT/US1992/005985
Other languages
English (en)
Other versions
WO1993001820A2 (fr
Inventor
Benson M Curtis
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of WO1993001820A2 publication Critical patent/WO1993001820A2/fr
Publication of WO1993001820A3 publication Critical patent/WO1993001820A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

On a isolé un récepteur non CD4-gp120 spécifique possédant une affinité de liaison spécifique envers la protéine de surface gp120 présente dans le virus du syndrome immunodéficitaire acquis (HIV). On décrit des méthodes de traitement de l'infection HIV dans les cellules négatives CD4, telles que celles du côlon et du cerveau, ainsi que des procédés de détection de l'HIV et des trousses diagnostic.
PCT/US1992/005985 1991-07-16 1992-07-16 Inhibition de l'infection hiv a mediation par la proteine non-cd4 WO1993001820A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73121491A 1991-07-16 1991-07-16
US731,214 1991-07-16

Publications (2)

Publication Number Publication Date
WO1993001820A2 WO1993001820A2 (fr) 1993-02-04
WO1993001820A3 true WO1993001820A3 (fr) 1993-05-27

Family

ID=24938578

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/005985 WO1993001820A2 (fr) 1991-07-16 1992-07-16 Inhibition de l'infection hiv a mediation par la proteine non-cd4

Country Status (7)

Country Link
AU (1) AU2373792A (fr)
IE (1) IE922308A1 (fr)
IL (1) IL102508A0 (fr)
MX (1) MX9204131A (fr)
PT (1) PT100694A (fr)
WO (1) WO1993001820A2 (fr)
ZA (1) ZA925305B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2224073A1 (fr) * 1995-06-09 1996-12-27 Francisco Veas Moyen pour detecter et prevenir une infection a vih, faisant appel a des recepteurs ou a des sites de fixation capables d'interagir avec gp120
FR2748483B1 (fr) * 1996-05-07 1998-07-24 Orstom Moyens pour la lutte ou le diagnostic d'une infection par hiv
EP1046651A1 (fr) 1999-04-19 2000-10-25 Koninklijke Universiteit Nijmegen Composition et méthode pour moduler l'interaction des cellules dendritiques et les cellules T
AUPQ278899A0 (en) * 1999-09-13 1999-10-07 Csl Limited Dendritic cell membrane protein cire
US7691591B2 (en) 2002-09-20 2010-04-06 Stichting Katholieke Universiteit Methods of identifying and isolating cells expressing DC-sign
WO2004026326A2 (fr) 2002-09-20 2004-04-01 Stichting Katholieke Universiteit Recepteur de capture d'antigene de candida albicans sur les cellules dendritiques
US7427469B2 (en) 2002-11-05 2008-09-23 Institut Pasteur Method of treating cytomegalovirus with DC-SIGN blockers
EP1562628B1 (fr) 2002-11-05 2009-04-15 Institut Pasteur Inhibiteurs de dc-sign et leur utilisation dans la prevention ou le traitement d'infections virales
US20080025913A1 (en) 2003-12-15 2008-01-31 Bowdish Katherine S Novel Anti-Dc-Sign Antibodies
US20060105063A1 (en) * 2004-11-18 2006-05-18 Kent Hann Synergic combination of compositions containing aloe vera isolates and their therapeutic application
GB0702183D0 (en) * 2007-02-05 2007-03-14 Iti Scotland Ltd Pathogen binding

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AIDS vol. 3, no. 12, 1989, pages 793 - 798 LARKIN. M. ET AL.; 'Oligosaccharide-mediated interactions of the envelope glycoprotein gp120 of HIV-1 that are independent of CD4 recognition"' cited in the application *
BULL. INST. PASTEUR vol. 89, no. 2, June 1991, IZRACHI, Y. ET AL.; 'Efficient binding , fusion and entry of HIV1 into CD4 negative neural cells : a mechanism for neuropathogenesis in Aids.' *
JOURNAL OF MEDICAL VIROLOGY vol. 35, no. 3, November 1991, pages 187 - 191 MORRISSON, N.K. ET AL.; 'Growth of human immunodeficiency virus 1 in cultured cells in the absence of the CD4 antigen."' *
NATURE. vol. 337, 1989, LONDON GB pages 368 - 370 CLAPHAM, P.R. ET AL.; 'Soluble CD4 blocks the infectivity of diverse strains of HIV and SIV for T cells and monocytes but not for brain and muscle cells.' cited in the application *
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA. vol. 89, September 1992, WASHINGTON US pages 8356 - 8360 Curtis, Benson M.; Scharnowske, S.; Watson, A.J.; 'Sequence and expression of a membrane-associated C-type lectin that exhibits CD4-independent binding of human immunodeficiency virus envelope glycoprotein gp120.' *
THE JOURNAL OF EXPERIMENTAL MEDECINE vol. 169, January 1989, THE ROCKEFELLER UNIV. PRESS pages 185 - 196 EZEKOWITZ, R.A.B. ET AL.; 'A human serum mannose binding protein inhibits in vitro infection by the human immunodeficeincy virus.' *

Also Published As

Publication number Publication date
MX9204131A (es) 1993-04-01
ZA925305B (en) 1993-06-14
IL102508A0 (en) 1993-01-14
AU2373792A (en) 1993-02-23
IE922308A1 (en) 1993-01-27
PT100694A (pt) 1993-10-29
WO1993001820A2 (fr) 1993-02-04

Similar Documents

Publication Publication Date Title
WO1988009181A3 (fr) Anticorps monoclonaux neutralisant le hiv-1
EP0887427A3 (fr) Amplification et détection du HIV-1 et/or HIV-2
CA2082948A1 (fr) Peptides et anticorps immunogenes et leurs utilisations pour la fixation au recepteur des cd4
WO1993001820A3 (fr) Inhibition de l'infection hiv a mediation par la proteine non-cd4
CA2143163A1 (fr) Peptides derives d'un retrovirus du groupe vih et leur utilisation
AU8083594A (en) Synthetic human neutralizing monoclonal antibodies to human immunodeficiency virus
AUPO784197A0 (en) Treatment of nasopharyngeal carcinoma
EP1026263A3 (fr) Amorces oligonucleotides pour la transkription inverse pour la detection efficace d'hiv-1 et hiv-2 et leurs usages
DK0479909T3 (da) Bispecifikke reagenser til AIDS-behandling
CA2363947A1 (fr) Peptides, antigenes du vih, compositions de vaccins afferentes, trousse de dosage immunologique et methode de detection d'anticorps induits par le vih
AU6891187A (en) Retrovirus of the hiv-2 type susceptible of inducing aids, and its antigenic and nucleic constituents
CA2082825A1 (fr) Inhibition de l'infection virale
CA2169603A1 (fr) Retrovirus du groupe vih et son utilisation
EP0344006A3 (fr) Peptides bloquant la liaison de HIV-1 vers CD4 du récepteur de protéine
WO1997046697A3 (fr) Anticorps diriges contre un complexe de cd4 et d'un domaine de recepteurs des chemokines, et leur utilisation pour lutter contre les infections a vih
WO1991015512A3 (fr) Polypeptides d'enveloppe du vih
AU7028998A (en) Retroviral vectors, method for the production and the use thereof for gene transfer in cd4-positive cells
EP0323157A3 (fr) Composés antiviraux et méthodes
EP0311108A3 (fr) Azido 3'-diamino-2,6-purine-didéoxy,2',3'-ribosides actifs contre HIV
EP0270114A3 (fr) Polypeptides ENV/GAG
AU5061090A (en) Aids therapy
AU2530795A (en) Assay for hiv-1 group o using at least one gp41 peptide
AU4959193A (en) High affinity, strongly neutralizing monoclonal antibodies against the CD-4 binding site of GP120 of human immunodeficiency virus
CA2274853A1 (fr) Constructions de peptides a plusieurs ramifications
AU8976691A (en) Selected peptides of the group-specific antigen (gag) of human immunodeficiency virus (hiv), the preparation and use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA FI JP KR NO

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA FI JP KR NO

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE

122 Ep: pct application non-entry in european phase
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA